Product
Favipiravir
Aliases
Avigan
14 clinical trials
7 indications
Indication
COVID-19Indication
InfluenzaIndication
HumanIndication
Crimean-Congo hemorrhagic feverIndication
Lassa feverIndication
Infectious DiseaseIndication
Respiratory Syncytial VirusClinical trial
Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)Status: Completed, Estimated PCD: 2021-10-20
Clinical trial
Control of COVID-19 Outbreaks in Long Term Care (CONTROL-COVID)Status: Terminated, Estimated PCD: 2021-10-30
Clinical trial
Randomized Open-label Multicenter Parallel-group Study of Efficacy and Safety of TL-FVP-t vs. Standard of Care Therapy in Patients With Mild to Moderate Coronavirus Disease (SARS-CoV-2/COVID-19)Status: Completed, Estimated PCD: 2020-07-29
Clinical trial
A Multi-center, Double-blinded, Randomized, Phase III Study to Evaluate the Efficacy and Safety of JT001 (VV116) Compared With Favipiravir in Participants With Moderate to Severe Coronavirus Disease 2019 (COVID-19)Status: Terminated, Estimated PCD: 2022-12-15
Clinical trial
A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patient Requiring Hospitalisation for Management of Moderate COVID-19 InfectionStatus: Terminated, Estimated PCD: 2023-03-01
Clinical trial
ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA)Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
UMIT-1 Trial: Favipiravir & Ribavirin Phase IB A Randomised Phase Ib Study to Determine the Phase II Dose and to Evaluate the Safety and Efficacy of Intravenous (IV) Favipiravir & RibavirinStatus: Recruiting, Estimated PCD: 2023-09-30
Clinical trial
Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African CountriesStatus: Not yet recruiting, Estimated PCD: 2027-06-01
Clinical trial
Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination (Casirivimab and Imdevimab) Versus Standard Antiviral Therapy (Remdesivir and Favipravir) as Antiviral Agent Against Corona Virus 2 Infection in Hospitalized COVID-19 PatientsStatus: Completed, Estimated PCD: 2022-12-28
Clinical trial
Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
Favipiravir and/or Nitazoxanide: a Randomized, Double-blind, Placebo-controlled Trial of Early Antiviral Therapy in COVID-19 (FANTAZE)Status: Completed, Estimated PCD: 2023-03-21
Clinical trial
Phase III, Random-Open, Clinical Trials on the Efficacy and Safety of Favipiravir in Covid-19 Patients in IndonesiaStatus: Completed, Estimated PCD: 2021-10-25
Clinical trial
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever: A Randomized Controlled Open Label Phase II Clinical TrialStatus: Completed, Estimated PCD: 2022-11-10
Clinical trial
Assessment of Respiratory SYNcytial Virus antivirALs: A Phase 2 Multi-centre Adaptive Randomised Platform Trial For the Assessment of Antiviral Pharmacodynamics in aCute Symptomatic RSV Infection (ARSYNAL-FC)Status: Not yet recruiting, Estimated PCD: 2027-01-01